p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma
Top Cited Papers
- 4 November 2011
- journal article
- research article
- Published by Elsevier BV in Laboratory Investigation
- Vol. 25 (3), 405-415
- https://doi.org/10.1038/modpathol.2011.173
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimensLaboratory Investigation, 2011
- Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung CancerCancer Discovery, 2011
- Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung CancerJournal of Thoracic Oncology, 2011
- Subclassification of Non-small Cell Lung Carcinomas Lacking Morphologic Differentiation on Biopsy SpecimensThe American Journal of Surgical Pathology, 2011
- Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung CancerScience Translational Medicine, 2010
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2010
- The Diagnostic Value of TTF-1, CK 5/6, and p63 Immunostaining in Classification of Lung CarcinomasApplied Immunohistochemistry & Molecular Morphology, 2007
- Cytology applications of p63 and TTF-1 immunostaining in differential diagnosis of lung cancersDiagnostic Cytopathology, 2005
- Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung CancersJNCI Journal of the National Cancer Institute, 2005
- Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung CancerJournal of Clinical Oncology, 2004